These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34237612)

  • 21. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of microsatellite instability in sporadic colon cancers.
    Sinicrope FA; Sargent DJ
    Curr Opin Oncol; 2009 Jul; 21(4):369-73. PubMed ID: 19444104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.
    Dienstmann R; Salazar R; Tabernero J
    J Clin Oncol; 2015 Jun; 33(16):1787-96. PubMed ID: 25918287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.
    Taieb J; André T; Auclin E
    Cancer Treat Rev; 2019 May; 75():1-11. PubMed ID: 30849607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.
    Baek DW; Kang BW; Lee SJ; Kim HJ; Park SY; Park JS; Choi GS; Baek JH; Kim JG
    In Vivo; 2019; 33(2):649-657. PubMed ID: 30804154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
    Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
    Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
    Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
    Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
    Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
    Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
    Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
    Bayir Garbioglu D; Demir N; Ozel C; Avci H; Dincer M
    FASEB J; 2021 Sep; 35(9):e21834. PubMed ID: 34403553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of molecular biomarkers to inform adjuvant therapy for colon cancer.
    Mettu NB; Hurwitz H; Hsu DS
    Oncology (Williston Park); 2013 Aug; 27(8):746-54. PubMed ID: 24133820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy for colon cancer.
    Aranha O; Benson AB
    Curr Gastroenterol Rep; 2007 Oct; 9(5):415-21. PubMed ID: 17991344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.